Sana Biotechnology Company Insiders

SANA Stock  USD 2.45  0.03  1.21%   
Sana Biotechnology employs about 328 people. The company is managed by 19 executives with a total tenure of roughly 766 years, averaging almost 40.0 years of service per executive, having 17.26 employees per reported executive. Analysis of Sana Biotechnology's management performance can provide insight into the company performance.

Sana Biotechnology's Insider Buying Vs Selling

50

 
Selling
 
Buying

Latest Trades

2024-09-24Richard MulliganDisposed 150000 @ 4.08View
2024-02-08Robert NelsenAcquired 1818181 @ 5.5View
Monitoring Sana Biotechnology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.

Sana Biotechnology Management Team Effectiveness

The company has return on total asset (ROA) of (0.3115) % which means that it has lost $0.3115 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.929) %, meaning that it created substantial loss on money invested by shareholders. Sana Biotechnology's management efficiency ratios could be used to measure how well Sana Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.81. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Sana Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 361.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 6.3 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 203.8 M, whereas Net Loss is forecasted to decline to (254.7 M).

Sana Biotechnology Workforce Comparison

Sana Biotechnology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 4,867. Sana Biotechnology holds roughly 328 in number of employees claiming about 7% of equities under Health Care industry.

Sana Biotechnology Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sana Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sana Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sana Biotechnology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.5
1
2
 4,911 
 300,000 
2024-03-01
19.0
19
1
 8,293,453 
 25,000 
2023-12-01
5.0
5
1
 39,002 
 75,000 
2023-09-01
0.4
2
5
 5,397 
 10,599,530 
2023-06-01
1.1
11
10
 1,630,030 
 949,000 
2022-03-01
10.0
10
1
 3,223,000 
 333.00 
2021-09-01
0.2941
5
17
 48,697 
 189,939 
2021-06-01
0.5
1
2
 12,500 
 334,000 
2021-03-01
0.75
39
52
 136,730,462 
 60,412,185 

Sana Biotechnology Notable Stakeholders

A Sana Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sana Biotechnology often face trade-offs trying to please all of them. Sana Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sana Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Steven MDCEO PresidentProfile
Nathan MBAExecutive CFOProfile
Susan WyrickTreasurer, CFOProfile
Sunil MDHead VPProfile
Christian MBAExecutive OfficerProfile
Shanna PeekSr OperationsProfile
Richard MulliganExecutive ResearchProfile
Sonja MDSenior PlatformProfile
Gary MDChief OfficerProfile
Farah AnwarHead OperationsProfile
John MDHead DevelopmentProfile
Terry MDSenior TherapeuticsProfile
Yuko JDHead PropertyProfile
Snehal PatelSenior OfficerProfile
Paul MDSenior ScienceProfile
Edward RebarHead EngineeringProfile
Brittany MccleeryAccounting MangProfile
Robin AndrulevichExecutive OfficerProfile
Bernard JDExec CounselProfile

About Sana Biotechnology Management Performance

The success or failure of an entity such as Sana Biotechnology often depends on how effective the management is. Sana Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sana management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sana management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.78)(0.81)
Return On Capital Employed(0.65)(0.69)
Return On Assets(0.50)(0.53)
Return On Equity(0.99)(0.94)
Please note, the presentation of Sana Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sana Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sana Biotechnology's management manipulating its earnings.

Sana Biotechnology Workforce Analysis

Traditionally, organizations such as Sana Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sana Biotechnology within its industry.

Sana Biotechnology Manpower Efficiency

Return on Sana Biotechnology Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee863.6K
Net Loss Per Executive14.9M
Working Capital Per Employee454.4K
Working Capital Per Executive7.8M

Complementary Tools for Sana Stock analysis

When running Sana Biotechnology's price analysis, check to measure Sana Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sana Biotechnology is operating at the current time. Most of Sana Biotechnology's value examination focuses on studying past and present price action to predict the probability of Sana Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sana Biotechnology's price. Additionally, you may evaluate how the addition of Sana Biotechnology to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum